P-glycoprotein in the placenta: expression, localization, regulation and function

Area of Science:

• Pharmacology
• Reproductive Biology
• Molecular Biology

Background:

• Understanding placental drug transfer is vital for safe and effective pregnancy pharmacotherapy.
• Drug efflux transporters are key components of the placental barrier, influencing fetal drug exposure.
• P-glycoprotein (P-gp, MDR1) is a well-characterized efflux transporter with a significant role in regulating materno-fetal drug disposition.

Purpose of the Study:

• To review the current knowledge on P-glycoprotein expression, localization, and function in the placenta.
• To summarize recent findings on the transcriptional regulation of placental P-gp and MDR1 gene polymorphisms.
• To discuss the clinical significance and future perspectives of placental P-gp in pregnancy pharmacotherapy.

Main Methods:

• Review of existing literature on P-glycoprotein in placental drug transport.
• Analysis of studies confirming P-gp expression at mRNA and protein levels throughout pregnancy.
• Evaluation of in vitro and in vivo data demonstrating functional P-gp activity in materno-fetal drug transport.

Main Results:

• P-glycoprotein expression is confirmed in the placental trophoblast layer across all stages of pregnancy.
• Functional studies demonstrate P-gp's active role in pumping xenobiotics from trophoblast cells back to maternal circulation.
• P-gp acts as a protective mechanism for the fetus by limiting drug transfer.

Conclusions:

• P-glycoprotein is a critical determinant of transplacental drug pharmacokinetics.
• Understanding placental P-gp regulation and polymorphisms is essential for optimizing drug therapy during pregnancy.
• Future research on placental P-gp holds promise for improved fetal pharmacotherapy.